Fact: Between 2005-2011, military prescriptions for psychiatric drugs increased nearly seven times (682%) – more than 30 times faster than the civilian rate. One in six American service members takes at least one psychiatric drug.
Fact: There are nearly 50 international drug-regulatory agency warnings that psychiatric drugs – including antidepressants – can cause suicidal thoughts and suicide.
Fact: In 2012, more active military died by suicide than from combat – nearly one a day. A total of 273 committed suicide in 2014, and 2015 is on track to post a similar number.
Fact: Military veterans are committing suicide at the staggering rate of 22 every day.
Fact: Some 80% of vets labeled with PTSD receive psychiatric drugs; 89% of them are given antidepressants. A questionnaire used to screen for depression and PTSD is copyrighted to Pfizer, the company that manufactures the antidepressant Zoloft and other psychiatric drugs.
Retired Army Colonel and psychologist Bart Billings says:
“If you take a look at people who commit suicide, most of those people – I would say as much as 80% – are on some type of psychiatric medication where there’s a black box warning…for suicidality, poor judgment and reasoning, anger and hostility, which can translate to homicide, depression, etc.”
“In my 47 years of treating people, although I had access to using psychiatric medication, I never recommended a single psychiatric drug. In all these years, I can state unequivocally, I therefore never had a person commit suicide or a homicide while in my care.”
“The Hidden Enemy: Inside Psychiatry’s Covert Agenda”
To view the Citizens Commission on Human Rights (CCHR) documentary detailing how psychiatry uses the military as its testing ground, click here and then click on “Military Documentary.”
If you or someone you know has been harmed by psychiatric drugs or other mental-health treatment, we want to talk to you. You can contact us privately by clicking here or by calling 303-789-5225. All information will be kept in the strictest confidence. We welcome your comments below.